Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Diabetes and cancer are both heterogeneous and multifactorial diseases with tremendous impact on health worldwide. Epidemiologic evidence suggests that certain malignancies may be associated with diabetes, as well as with diabetes risk factors and, perhaps, with certain diabetes treatments. Numerous biological mechanisms could account for these relationships. Insulin‐like growth factor (IGF)‐1, IGF‐2, IGF‐1 receptors, insulin, and the insulin receptor play roles in the development and progression of cancers. Although evidence from randomized controlled trials does not support or refute associations of diabetes and its treatments with either increased or reduced risk of cancer incidence or prognosis, consideration of malignancy incidence rates and the magnitude of the trials that would be required to address these issues explains why such studies may not be readily undertaken.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 1×
“Inflammatory cytokines include interleukin (IL)-6, which activates Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) signaling,(151) and tumor necrosis factor (TNF)-α, which binds to TNF receptors and activates nuclear factor-κB.(152) These pathways can promote proliferation and metas…”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“(SUs) will accelerate the presentation and growth rate of cancers.(93) Treatment with SUs may lead to increased insulin and IGF-1 levels and decreased IGFBP-1 levels, T.”
BackgroundType-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Sjöström, L., Gummesson, A., Sjöström, C. D., Narbro, K., Peltonen, M., Wedel, H., Bengtsson, C., Bouchard, C., Carlsson, B., Dahlgren, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70159-7 · Cited by 770
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607 · cited 2×
“Among the previous studies, a German study reported an excess cancer incidence only when the insulin dose was taken into account.(78) A Swedish study reported a greater incidence of breast cancer only, but not of all cancers or any other cancer.”
BackgroundMetformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Obesity and cancer risk: the role of the insulin-IGF axis
Renehan, A. G., Frystyk, J., & Flyvbjerg, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.08.006 · Cited by 480
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460 · cited 1×
“ated with adiposity, and obesity-related breast cancers are more likely to be ER positive.(159) Estrogen stimulates cell proliferation mainly by activating ER transcription”
BackgroundJonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Elevated insulin receptor content in human breast cancer
Papa, V, Pezzino, V, Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R., Goldfine, I. D., & Vigneri, R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114868 · Cited by 338 · cited 1×
“IR-A may mediate the effects of IGF-2 on cell proliferation in cancer and embryonic development,(138) and IR-A overexpression may be important in mediating the biological effects of IGF-2 and may actually confer a selective advantage to cancer cells.(139) Many malignancies, including cancers of the breast, colon, lung…”
BackgroundLukanova, A., Lundin, E., Zeleniuch-Jacquotte, A., Muti, P., Mure, A., Rinaldi, S., Dossus, L., Micheli, A., Arslan, A., Lenner, P., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500161 · Cited by 315 · cited 1×
“resistance, and diabetes that contribute to hyperinsulinemia favor the development of malignancies.(148,149)”
BackgroundNeumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284 · cited 1×
“79).(71) However, a study conducted in Taiwan, which provided the first data in Asians,”
ResultSulphonylureas and cancer: a case-control study
Monami, M., Lamanna, C., Balzi, D., Marchionni, N., & Mannucci, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-008-0083-2 · Cited by 194
Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1452-2 · Cited by 141
Pioglitazone and Bladder Cancer
Tseng, C.-H. (2012) · Diabetes Care · doi:10.2337/dc11-1449 · Cited by 123
Rosiglitazone and Risk of Cancer
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008) · Diabetes Care · doi:10.2337/dc07-2308 · Cited by 97
Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Dandona, P., Dhindsa, S., Chaudhuri, A., Bhatia, V., Topiwala, S., & Mohanty, P. (2008) · Current Molecular Medicine · doi:10.2174/156652408786733658 · Cited by 94
Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes
Chen, S.-W., Tsan, Y.-T., Chen, J.-D., Hsieh, H.-I., Lee, C.-H., Lin, H.-H., Wang, J.-D., Chen, P.-C., & Health Data Analysis in Taiwan Research Group (2013) · Diabetes Care · doi:10.2337/dc11-2197 · Cited by 37 · cited 1×
“A recent Taiwanese case-control study also confirmed that the use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes.(67) For bladder cancer risk, rosiglitazone use was not significantly associated with elevated bladder cancer risk,(68) whereas controversy remains as to whet…”
Background
Research works printed but not linked: 142
- 10.1001/jama.293.2.194 · DOI · Paper page
- 10.1007/s00125-006-0207-6 · DOI · Paper page
- 10.2337/dc06-0922 · DOI · Paper page
- Tulinius H, 1997, Risk factors for malignant diseases: A cohort study on a population of 22 946 Icelanders, Cancer Epidemiol Biomarkers Prev, 6, 863
- 10.1093/oxfordjournals.aje.a115495 · DOI · Paper page
- 10.1093/aje/kwg100 · DOI · Paper page
- 10.1371/journal.pmed.1000201 · DOI · Paper page
- 10.1002/ijc.22717 · DOI · Paper page
- 10.1007/s00125-006-0468-0 · DOI · Paper page
- 10.1007/s00125-007-0681-5 · DOI · Paper page
- 10.1016/j.cgh.2005.12.007 · DOI · Paper page
- 10.1007/s00125-004-1415-6 · DOI · Paper page
- 10.1093/aje/kwp003 · DOI · Paper page
- 10.1093/aje/kwj311 · DOI · Paper page
- 10.1023/A:1011279907108 · DOI
- 10.1016/j.ejca.2005.09.003 · DOI · Paper page
- 10.1016/j.ijrobp.2009.06.051 · DOI
- 10.1038/pcan.2009.39 · DOI
- World Cancer Research Fund/American Institute for Cancer Research, 2007, Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective
- 10.1158/1055-9965.EPI-12-0485 · DOI · Paper page
- 10.1016/S0140-6736(08)60269-X · DOI · Paper page
- 10.1038/oby.2005.177 · DOI · Paper page
- 10.1007/s10549-012-2187-1 · DOI
- 10.1038/oby.2008.610 · DOI · Paper page
- 10.1097/SLA.0b013e3181e33778 · DOI
- 10.1016/j.soard.2008.08.025 · DOI · Paper page
- 10.1111/j.1467-789X.2012.01010.x · DOI · Paper page
- 10.1080/13813450902878054 · DOI · Paper page
- 10.3109/10408368409165766 · DOI · Paper page
- 10.1055/s-0031-1295414 · doi:10.1055/s-0031-1295414
- 10.1371/journal.pone.0018134 · DOI · Paper page
- 10.1016/j.regpep.2008.10.008 · DOI
- 10.2337/dc12-1316 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-2946 · DOI · Paper page
- 10.1158/1055-9965.EPI-07-0182 · DOI · Paper page
- 10.1002/ijc.21861 · DOI · Paper page
- 10.1093/jnci/djn415 · DOI · Paper page
- 10.1002/ijc.22578 · DOI · Paper page
- 10.1158/1055-9965.EPI-07-2686 · DOI · Paper page
- Muti P, 2002, Fasting glucose is a risk factor for breast cancer: A prospective study, Cancer Epidemiol Biomarkers Prev, 11, 1361
- 10.7326/0003-4819-149-7-200810070-00006 · DOI
- 10.1016/j.tcb.2008.01.008 · DOI
- 10.2337/dc11-0512 · DOI · Paper page
- 10.1200/JCO.2011.39.7505 · DOI · Paper page
- 10.1007/s10549-012-2170-x · DOI · Paper page
- 10.1186/1471-2407-12-410 · DOI · Paper page
- 10.1038/ajg.2011.483 · DOI · Paper page
- 10.1016/j.ygyno.2011.06.038 · DOI · Paper page
- 10.1038/ajg.2013.5 · DOI · Paper page
- 10.3109/0284186X.2012.718096 · DOI · Paper page
- 10.1093/annonc/mdr020 · DOI
- 10.1093/annonc/mdr534 · DOI · Paper page
- Kubota T, 1998, Ligand for peroxisome proliferator‐activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo, Cancer Res, 58, 3344
- 10.1210/jc.86.5.2170 · doi:10.1210/jc.86.5.2170
- 10.1634/theoncologist.2012-0302 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-4277 · DOI · Paper page
- 10.1038/onc.2011.299 · DOI
- 10.1002/hep.23669 · DOI
- 10.1038/bjc.2012.130 · DOI
- 10.1503/cmaj.112102 · DOI · Paper page
- 10.1001/jama.2011.939 · DOI
- 10.1111/dme.12144 · DOI · Paper page
- 10.2337/dc10-0476 · DOI
- 10.2337/dc12-1432 · DOI
- 10.2337/db09-1371 · DOI · Paper page
- 10.1371/journal.pone.0053411 · DOI · Paper page
- 10.1136/bmjopen-2011-000433 · DOI
- 10.1210/jc.2012-1162 · DOI · Paper page
- 10.1016/j.metabol.2010.09.012 · DOI
- 10.1371/journal.pone.0041992 · DOI
- 10.2337/dc12-0270 · DOI
- 10.1007/s00125-009-1453-1 · DOI · Paper page
- 10.1007/s00125-011-2312-4 · DOI
- 10.3109/0284186X.2011.624118 · DOI
- 10.1007/s00125-011-2429-5 · DOI
- 10.1016/S0140-6736(09)61307-6 · DOI
- 10.1111/j.1753-0407.2009.00038.x · DOI
- 10.1038/nrc3215 · DOI · Paper page
- 10.1038/ajg.2013.7 · DOI · Paper page
- 10.1016/j.metabol.2013.01.014 · DOI · Paper page
- 10.1634/theoncologist.2011-0462 · DOI · Paper page
- 10.1016/j.diabres.2010.08.022 · DOI
- 10.1016/j.cbi.2006.07.006 · DOI
- 10.1007/s00125-012-2653-7 · DOI · Paper page
- 10.1007/s00125-010-1804-y · DOI · Paper page
- 10.1007/s00125-009-1530-5 · DOI · Paper page
- 10.1007/s00125-010-1933-3 · DOI
- 10.1056/NEJMoa0802987 · DOI · Paper page
- 10.1016/S0140-6736(05)67528-9 · DOI · Paper page
- 10.1016/S0140-6736(09)60953-3 · DOI · Paper page
- 10.1136/bmj.e5278 · DOI · Paper page
- 10.1002/j.1460-2075.1986.tb04528.x · DOI · Paper page
- 10.1007/PL00000744 · DOI · Paper page
- 10.1158/1078-0432.CCR-07-4879 · DOI · Paper page
- 10.1016/S0960-9822(01)00068-9 · DOI · Paper page
- 10.1073/pnas.0403328101 · DOI · Paper page
- 10.1016/S0968-0004(02)02113-8 · DOI · Paper page
- 10.1210/endo.139.3.5832 · doi:10.1210/endo.139.3.5832 · Paper page
- 10.1023/A:1009523501499 · DOI · Paper page
- 10.1016/j.febslet.2004.08.013 · DOI · Paper page
- 10.1038/sj.cdd.4401839 · DOI
- 10.1128/MCB.19.5.3278 · DOI · Paper page
- 10.1136/mp.54.3.121 · DOI · Paper page
- Vella V, 2002, A novel autocrine loop involving IGF‐II and the insulin receptor isoform‐A stimulates growth of thyroid cancer, J Clin Endocrinol Metab, 87, 245, 10.1210/jcem.87.1.8142 · doi:10.1210/jcem.87.1.8142 · Paper page
- Mathieu MC, 1997, Insulin receptor expression and clinical outcome in node‐negative breast cancer, Proc Assoc Am Physicians, 109, 565
- 10.1002/j.1460-2075.1990.tb07416.x · DOI · Paper page
- 10.1016/0006-291X(89)92439-X · DOI · Paper page
- 10.1055/s-2004-814157 · DOI
- 10.1210/mend-3-8-1263 · DOI · Paper page
- 10.1210/me.2004-0183 · DOI · Paper page
- 10.1210/mend-5-5-734 · DOI
- 10.1210/en.132.3.1132 · doi:10.1210/en.132.3.1132
- 10.1210/en.2002-0136 · DOI
- 10.1172/JCI115819 · DOI · Paper page
- 10.2337/diab.42.5.675 · DOI
- 10.1007/BF00403966 · DOI
- 10.1371/journal.pone.0027488 · DOI · Paper page
- 10.1080/13813450801969715 · DOI · Paper page
- 10.1038/sj.onc.1202600 · DOI · Paper page
- 10.1038/sj.onc.1206058 · DOI · Paper page
- 10.1210/en.2001-211408 · DOI · Paper page
- 10.2337/diacare.13.6.576 · doi:10.2337/diacare.13.6.576
- 10.1042/bj2900419 · DOI · Paper page
- Pandini G, 1999, Insulin and insulin‐like growth factor‐I (IGF‐I) receptor overexpression in breast cancers leads to insulin/IGF‐I hybrid receptor overexpression: Evidence for a second mechanism of IGF‐I signaling, Clin Cancer Res, 5, 1935
- 10.1016/S0300-9084(99)80088-1 · DOI
- 10.1074/jbc.M202766200 · DOI · Paper page
- 10.1002/ijc.22697 · DOI · Paper page
- 10.1038/nrc3174 · DOI · Paper page
- 10.1056/NEJMoa1006312 · DOI · Paper page
- 10.1053/gast.2001.25490 · DOI · Paper page
- 10.1136/gut.2010.235754 · DOI · Paper page
- 10.1210/jc.2004-0297 · DOI
- 10.1074/jbc.M313191200 · DOI · Paper page
- 10.1016/j.bbapap.2009.09.012 · DOI · Paper page
- 10.1371/journal.pone.0004968 · DOI
- 10.1074/jbc.275.17.12565 · DOI
- 10.1007/s12032-012-0198-8 · doi:10.1007/s12032-012-0198-8
- Osborne CK, 2005, Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer, Clin Cancer Res, 11, 865s, 10.1158/1078-0432.865s.11.2 · DOI · Paper page
- 10.3109/08977194.2011.565003 · DOI
- 10.1016/j.mce.2004.08.002 · DOI
- 10.1074/jbc.M109592200 · DOI · Paper page
- 10.1038/nrc1408 · DOI · Paper page
Cited by
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose
García-Jiménez, C., García-Martínez, J. M., Chocarro-Calvo, A., & De la Vieja, A. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0152 · Cited by 151
Diabetes and Cancer: 5 Years Into the Recent Controversy
Badrick, E., & Renehan, A. G. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.032 · Cited by 53
Metadata
- Authors
- Wang, T., Ning, G., & Bloomgarden, Z.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2013-06-05
- Volume
- 5
- Issue
- 4
- Pages
- 378-390
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W1492825867
- Cited by
- 21
- References
- 24
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.